Clinical Trial Update: Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update reports on the study of Foretinib in combination with Lapatinib for metastatic breast cancer (Phase 1/2) which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Foretinib (foretinib)
• Lapatinib (Lapatinib)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED